drugset / Trial / NCT00861692

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

NCT00861692

Phase 2 Completed 20 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy

Timeline

Start
2009-04
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Argatroban Small molecule 0.77 ug/kg Other